Modis Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Modis Therapeutics, Inc. - overview
Established
2016
Location
Oakland, CA, US
Primary Industry
Biotechnology
About
Modis Therapeutics, Inc. specializes in innovative therapeutic solutions to address unmet medical needs, focusing on developing treatments for neurological disorders and rare diseases. Their commitment to advancing healthcare is reflected in their strategic initiatives. Founded in 2016 in Oakland, US, Modis Therapeutics, Inc.
is focused on advancing therapeutic solutions in the medical field. The firm has undergone no significant pivots in its strategy and does not have publicly known subsidiaries. The company, founded by Peter Barber, has completed 2 deals, with the most recent one on August 26, 2019. On that date, Zogenix, Inc.
entered into a definitive agreement to acquire Modis Therapeutics for USD 250. 000 mn, marking a significant milestone in the firm's financial trajectory. The total amount raised by the company stands at USD 250. 000 mn.
Modis Therapeutics, Inc. primarily focuses on developing therapeutic solutions for neurological disorders and rare diseases. Their offerings target healthcare providers and patients in need of advanced treatments. The products under development are aimed at improving patient outcomes and quality of life, catering to both individual and institutional needs within the healthcare sector.
The revenue structure for Modis Therapeutics is based on the success of their therapeutic products once brought to market. The recent acquisition by Zogenix Inc. for USD 250. 000 mn indicates the value of their proprietary technologies and potential revenue streams derived from successful treatments.
Modis Therapeutics aims to intensify its research and development efforts to advance its pipeline of therapeutic solutions, with specific plans to launch new products targeting neurological disorders. The funding from the recent acquisition will be utilized to support ongoing clinical trials and further market expansion into regions with high unmet medical needs. The company strategizes to enhance its footprint in North America and Western Europe by 2023, focusing on regions with robust healthcare infrastructure.
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.modistx.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.